MedTrace Logo

Safety and Efficacy of Nemolizumab in PN

NCT03181503 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2020-02-19

Study results available
· View outcomes & findings →

Summary

The aim of this study is to assess the safety and efficacy of nemolizumab in subjects with prurigo nodularis.

Conditions

  • Prurigo Nodularis

Interventions

DRUG

CD14152 Dose A

3 subcutaneous injections (every 4 weeks during the 12-week treatment period)

DRUG

CD14152 placebo

3 subcutaneous injections (every 4 weeks during the 12-week treatment period)

Sponsors & Collaborators

  • Galderma R&D

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-02
Primary Completion
2018-09-26
Completion
2018-09-26
FDA Drug
Yes

Countries

  • Austria
  • France
  • Germany
  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03181503 on ClinicalTrials.gov